Drug intelligence / Profile preview

br6001-2

Development stage: Phase 1
Lead developer: Boryung
Modality: Small Molecules

Overview

BR6001-2 is a component of the investigational drug combination "BR6001" developed by Boryung Corp. for digestive system disorders. The specific mechanism of action and target are not publicly disclosed in available sources. Clinical trials have evaluated the drug-drug interaction and safety between "BR6001-1" and "BR6001-2" in healthy adult volunteers, with indications including gastric or duodenal ulcer[10][1]. The drug is classified as a small molecule.

Other names: BR 6001BR6001BR-6001BR6001-2BR-6001-2BR 6001-2

Beyond the preview

Go deeper on br6001-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on br6001-2.

Explore the full profile